HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Efficacy and feasibility of procarbazine, ranimustine and vincristine chemotherapy, and the role of surgical resection in anaplastic oligodendroglioma.

AbstractUNLABELLED:
The safety, tolerance and preliminary efficacy of a chemotherapy regimen consisting of procarbazine (PCB), ranimustine (MCNU) and vincristine (VCR) were assessed for patients with newly diagnosed supratentorial anaplastic oligodendroglioma.
MATERIALS AND METHODS:
Between October 1999 and September 2003, 5 patients were enrolled. The initial regimens were prescribed as adjuvant therapy in conjunction with radiotherapy following standard surgical treatment. All patients received a chemotherapy comprising ranimustine (100 mg/m2) intravenously on Day 1, procarbazine (60 mg/m2) on Days 8 to 21, and vincristine (1.4 mg/m2, maximum total 2 mg) on Days 8 and 29. The cycles were repeated every 8 weeks until tumor progression was evident, or for a total of 6 cycles over a 1-year period. The primary end-points were safety and tolerability, while the secondary end-point was overall survival.
RESULTS:
Five consecutive eligible patients were treated. Of the 4 evaluable patients, 3 partially responded to the treatment (PR), while 1 had a complete response (CR): all patients are still alive. However, 3 of the 5 patients showed relapse, with a time to tumor progression (TTP) of 50, 143 and 241 weeks, respectively. Two of these patients received combined treatment with carboplatin, etoposide and recombinant human mutant tumor necrosis factor-alpha at the first relapse. This regimen appeared to be safe and neither neurological toxicity, severe or life-threatening hematological toxicity, nor fatal toxicity (WHO Grade 4) were experienced.
CONCLUSION:
These results suggest that a chemotherapy regimen consisting of PCB, MCNU and VCR in this patient population seems to be safe and tolerable, and the response rate was high. Thus, wide resection with a risk of major neurological morbidity due to nearby functionally critical areas can be avoided. However, since the relapse rate was high, a second-line chemotherapy should be developed for anaplastic oligodendroglioma to improve the long-term control of the disease.
AuthorsMasaaki Yamamoto, Mitsutoshi Iwaasa, Masani Nonaka, Hitoshi Tsugu, Kazuki Nabeshima, Takeo Fukushima
JournalAnticancer research (Anticancer Res) 2005 Nov-Dec Vol. 25 Issue 6A Pg. 3715-23 ISSN: 0250-7005 [Print] Greece
PMID16302731 (Publication Type: Clinical Trial, Journal Article)
Chemical References
  • Nitrosourea Compounds
  • Procarbazine
  • Vincristine
  • ranimustine
Topics
  • Adult
  • Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
  • Brain Neoplasms (drug therapy, radiotherapy, surgery)
  • Combined Modality Therapy
  • Female
  • Humans
  • Male
  • Middle Aged
  • Nitrosourea Compounds (administration & dosage, adverse effects)
  • Oligodendroglioma (drug therapy, radiotherapy, surgery)
  • Procarbazine (administration & dosage, adverse effects)
  • Treatment Outcome
  • Vincristine (administration & dosage, adverse effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: